healthcare

healthcare Articles

Spectrum Pharma shares dipped on Thursday after the firm announced a key update from the FDA on its treatment of neutropenia in breast cancer patients.
The December 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The December 14 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Gritstone shares made a handy gain on Friday after the firm received a key update from the FDA.
Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff.
GlaxoSmithKline shares bounced higher on Wednesday after the company announced a new joint venture with Pfizer. These two firms will create a premier global consumer health care company combining...
Tilray shares made a solid gain on Tuesday after the company announced that it entered a global agreement to collaborate with Sandoz, a subsidiary of Novartis.
Proteostasis Therapeutics shares jumped on Monday after the company announced that a new licensing agreement with Genentech.
A federal district court judge in Texas had declared the Affordable Care Act (aka, Obamacare) unconstitutional in a ruling that is taking a bite out of shares in insurance and hospital firms Monday.
Eli Lilly shares were slightly lower after the company announced positive results from its late-stage active psoriatic arthritis study.
Johnson & Johnson shares dropped on Friday after it came public that the company knew for decades that its baby powder sometimes contained the known carcinogen asbestos.
Eli Lilly shares rose slightly on Thursday after the company announced an FDA update on its treatment for systemic lupus erythematosus.
Applied Genetic Technologies shares dropped on Thursday after the company announced that its midstage eye study did not live up to expectations.
Marinus shares backed off on Wednesday when the firm announced that it would be conducting a secondary offering. The company is capitalizing on its success earlier this week when it announced...
Neurocrine Bio shares dipped on Wednesday after the company announced that its midstage Tourette syndrome study did not live up to expectations.